Zawya16d
FDA approves Tirzepatideas: The first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity
This approval was based on results from the SURMOUNT-OSA phase 3 clinical trials, which evaluated Tirzepatide (10 mg or 15 mg) for the treatment of moderate-to-severe OSA in adults with obesity, with ...
Endocrinology Advisor14d
Risk for Pancreatitis Does Not Increase With Tirzepatide
Higher doses of tirzepatide were particularly effective, with mean fasting insulin percent reductions of 27.76% (P =.003; 10 mg dose) and 37.0% (P <.00001; 15 mg dose) compared with placebo. All doses ...
ENDPOINTS NEWS8h
Semaglu­tide, tirzepatide com­pounder hit with FDA warn­ing let­ter
Compounding facility ProRx Pharmacy Network has received an FDA warning letter over issues with its semaglutide and ...
JD Supra26d
FDA Announced Removal of Tirzepatide from the Drug Shortage List
On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a declaratory order determining that the shortage of diabetes and weight-loss tirzepatide ... mg/0.5 mL, 7.5 mg/0.5 mL, 10 ...
Healthline5d
Mounjaro Injection Overview
Mounjaro (tirzepatide) is a prescription drug used ... Your doctor will likely have you start treatment with a 2.5-mg dose of Mounjaro. After 4 weeks of treatment, they’ll increase your dose ...
pharmaphorum7d
Lilly says tirzepatide staves off diabetes in phase 3 trial
Eli Lilly's latest clinical readout for dual GIP/GLP-1 agonist tirzepatide is a big one, with data suggesting the drug can reduce the risk of developing type 2 diabetes in overweight and obese ...
Morningstar14d
Lexaria's Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound(R)
Likewise, the injected Zepbound® resulted in 22 gastrointestinal ("GI")-related adverse events, whereas the oral DehydraTECH-tirzepatide resulted in only 10 GI-related ... in mg/dL) were 88.2 ...